Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

English | Polski
Przejdź do strony domowej biblioteki Biblioteka UWSB Merito Chorzów

Prolib Integro - strona głównaBiblioteka UWSB Merito Chorzów

Przeglądasz jako GOŚĆ

Wyszukujesz frazę ""SCHIZOPHRENIA"" wg kryterium: Temat

  Lista filtrów

Ogranicz do:

Wyrównaj
Wyświetlanie 1-20 z 717440

Starter badań:

Podgląd okładki
Tytuł :
Multiple serum anti-glutamate receptor antibody levels in clozapine-treated/naïve patients with treatment-resistant schizophrenia.
Autorzy :
He J; Department of Psychiatry, Sir Run-Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou, China.; Department of Psychiatry, National Clinical Research Center for Mental Disorders, and National Center for Mental Disorders, The Second Xiangya Hospital of Central South University, Changsha, China.
Li J; Department of Psychiatry, National Clinical Research Center for Mental Disorders, and National Center for Mental Disorders, The Second Xiangya Hospital of Central South University, Changsha, China.; Affiliated Wuhan Mental Health Center, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Wei Y; Department of Psychiatry, National Clinical Research Center for Mental Disorders, and National Center for Mental Disorders, The Second Xiangya Hospital of Central South University, Changsha, China.; Department of Psychiatry, Jiangxi Provincial People's Hospital, The First Affiliated Hospital of Nanchang Medical College, Nanchang, China.
He Z; Department of Psychiatry, Sir Run-Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou, China.; School of Mental Health, Wenzhou Medical University, Wenzhou, China.
Liu J; Department of Psychiatry, National Clinical Research Center for Mental Disorders, and National Center for Mental Disorders, The Second Xiangya Hospital of Central South University, Changsha, China.; Xiangya Nursing School of Central South University, Changsha, China.
Yuan N; Hunan Provincial Brain Hospital (The second people's Hospital of Hunan Province), Changsha, China.
Zhou R; The Ninth Hospital of Changsha, Changsha, China.
He X; The Ninth Hospital of Changsha, Changsha, China.
Ren H; Department of Psychiatry, National Clinical Research Center for Mental Disorders, and National Center for Mental Disorders, The Second Xiangya Hospital of Central South University, Changsha, China.; Department of Psychiatry, Shandong Provincial Hospital, Shandong University, Jinan, China.
Gu L; RIKEN Center for Advanced Intelligence Project, Tokyo, Japan.; Research Center for Advanced Science and Technology (RCAST), University of Tokyo, Tokyo, Japan.
Liao Y; Department of Psychiatry, Sir Run-Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou, China.
Chen X; Department of Psychiatry, National Clinical Research Center for Mental Disorders, and National Center for Mental Disorders, The Second Xiangya Hospital of Central South University, Changsha, China. .
Tang J; Department of Psychiatry, Sir Run-Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou, China. .; Hunan Provincial Brain Hospital (The second people's Hospital of Hunan Province), Changsha, China. .; Zigong Mental Health Center, Zigong, China. .
Pokaż więcej
Źródło :
BMC psychiatry [BMC Psychiatry] 2024 Apr 02; Vol. 24 (1), pp. 248. Date of Electronic Publication: 2024 Apr 02.
Typ publikacji :
Journal Article
MeSH Terms :
Clozapine*/adverse effects
Schizophrenia*/drug therapy
Schizophrenia*/diagnosis
Antipsychotic Agents*/adverse effects
Humans ; Schizophrenia, Treatment-Resistant ; Receptors, Glutamate/therapeutic use ; Glutamic Acid
Czasopismo naukowe
Szczegóły Pełny tekst Pełny tekst
Podgląd okładki
Tytuł :
Transient Fever Response After ECT in a Patient with Catatonic Schizophrenia: A Case Report.
Autorzy :
Alp A
Doğan MK
Eroğlu EÖ
Yildiz Mİ
Gürel ŞC
Özer S
Pokaż więcej
Transliterated Title :
Katatonik Şizofreni Hastasında EKT Sonrası Ortaya Çıkan Geçici Ateş Yanıtı: Olgu Sunumu.
Źródło :
Turk psikiyatri dergisi = Turkish journal of psychiatry [Turk Psikiyatri Derg] 2024 Spring; Vol. 35 (1), pp. 78-82.
Typ publikacji :
Journal Article; Case Reports
MeSH Terms :
Catatonia*/etiology
Catatonia*/therapy
Catatonia*/diagnosis
Schizophrenia*/complications
Schizophrenia*/therapy
Electroconvulsive Therapy*/adverse effects
Electroconvulsive Therapy*/methods
Neuroleptic Malignant Syndrome*/complications
Neuroleptic Malignant Syndrome*/diagnosis
Humans ; Schizophrenia, Catatonic/complications ; Schizophrenia, Catatonic/therapy
Czasopismo naukowe
Szczegóły
Podgląd okładki
Tytuł :
Palliative psychiatry for a patient with treatment-refractory schizophrenia and severe chronic malignant catatonia: case report.
Autorzy :
Elgudin J; Department of Psychiatry, New York-Presbyterian/Weill Cornell Medicine, New York, NY, USA.
Johnsen C; Department of Psychiatry, Weill Cornell Medicine, New York, NY, USA.
Westermair AL; Clinical Ethics Unit, University Hospital Basel (USB), University Psychiatric Clinics (UPK) Basel, University Children's Hospital Basel (UKBB), Geriatric University Medicine Felix Platter (UAFP), Basel, Switzerland; Institute of Biomedical Ethics and History of Medicine (IBME), University of Zurich (UZH), Zurich, Switzerland.
Trachsel M; Clinical Ethics Unit, University Hospital Basel (USB), University Psychiatric Clinics (UPK) Basel, University Children's Hospital Basel (UKBB), Geriatric University Medicine Felix Platter (UAFP), Basel, Switzerland; Medical Faculty, University of Basel, Basel, Switzerland.
Pokaż więcej
Źródło :
Annals of palliative medicine [Ann Palliat Med] 2024 Mar; Vol. 13 (2), pp. 433-439. Date of Electronic Publication: 2024 Mar 19.
Typ publikacji :
Case Reports; Journal Article
MeSH Terms :
Catatonia*/diagnosis
Catatonia*/drug therapy
Schizophrenia*/therapy
Schizophrenia*/drug therapy
Psychiatry*
Male ; Humans ; Middle Aged ; Schizophrenia, Treatment-Resistant ; Quality of Life/psychology
Czasopismo naukowe
Szczegóły
Podgląd okładki
Tytuł :
Gene expression imputation provides clinical and biological insights into treatment-resistant schizophrenia polygenic risk.
Autorzy :
Prohens L; Department of Clinical Foundations, Pharmacology Unit, University of Barcelona, Barcelona, Spain.
Rodríguez N; Department of Clinical Foundations, Pharmacology Unit, University of Barcelona, Barcelona, Spain; Institut d'investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.
Segura ÀG; Department of Clinical Foundations, Pharmacology Unit, University of Barcelona, Barcelona, Spain.
Martínez-Pinteño A; Department of Clinical Foundations, Pharmacology Unit, University of Barcelona, Barcelona, Spain; Institut d'investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.
Olivares-Berjaga D; Department of Clinical Foundations, Pharmacology Unit, University of Barcelona, Barcelona, Spain.
Martínez I; Institut d'investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.
González A; Institut d'investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.
Mezquida G; Department of Clinical Foundations, Pharmacology Unit, University of Barcelona, Barcelona, Spain; Institut d'investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain; Centro de Investigación Biomédica en red en salud Mental (CIBERSAM), ISCIII, Spain; Barcelona Clínic Schizophrenia Unit (BCSU), Neuroscience Institute, Hospital Clínic de Barcelona, Barcelona, Spain.
Parellada M; Centro de Investigación Biomédica en red en salud Mental (CIBERSAM), ISCIII, Spain; Department of Child and Adolescent Psychiatry, Institute of Psychiatry and Mental Health, Hospital General Universitario Gregorio Marañón, IiSGM, Madrid, Spain; School of Medicine, Universidad Complutense, Madrid, Spain.
Cuesta MJ; Centro de Investigación Biomédica en red en salud Mental (CIBERSAM), ISCIII, Spain; Department of Psychiatry, Hospital Universitario de Navarra, Pamplona, Spain; Navarra Institute for Health Research (IdiSNA), Pamplona, Spain.
Bernardo M; Institut d'investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain; Centro de Investigación Biomédica en red en salud Mental (CIBERSAM), ISCIII, Spain; Barcelona Clínic Schizophrenia Unit (BCSU), Neuroscience Institute, Hospital Clínic de Barcelona, Barcelona, Spain; Department of Medicine, University of Barcelona, Barcelona, Spain.
Gassó P; Department of Clinical Foundations, Pharmacology Unit, University of Barcelona, Barcelona, Spain; Institut d'investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain; Centro de Investigación Biomédica en red en salud Mental (CIBERSAM), ISCIII, Spain.
Mas S; Department of Clinical Foundations, Pharmacology Unit, University of Barcelona, Barcelona, Spain; Institut d'investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain; Centro de Investigación Biomédica en red en salud Mental (CIBERSAM), ISCIII, Spain. Electronic address: .
Pokaż więcej
Źródło :
Psychiatry research [Psychiatry Res] 2024 Feb; Vol. 332, pp. 115722. Date of Electronic Publication: 2024 Jan 05.
Typ publikacji :
Journal Article
MeSH Terms :
Schizophrenia*/genetics
Schizophrenia*/diagnosis
Psychotic Disorders*/psychology
Humans ; Schizophrenia, Treatment-Resistant ; Genome-Wide Association Study ; Genetic Risk Score ; Gene Expression
Czasopismo naukowe
Szczegóły
Podgląd okładki
Tytuł :
Role of the immune-kynurenine pathway in treatment-resistant schizophrenia.
Autorzy :
Chen W; Peking University HuiLongGuan Clinical Medical School, Beijing Huilongguan Hospital, Beijing, China.
Tian Y; Department of Human Reproductive Medicine, Beijing Obstetrics and Gynecology Hospital, Capital Medical University, Beijing, China; Beijing Maternal and Child Health Care Hospital, Beijing, China.
Gou M; Peking University HuiLongGuan Clinical Medical School, Beijing Huilongguan Hospital, Beijing, China.
Wang L; Peking University HuiLongGuan Clinical Medical School, Beijing Huilongguan Hospital, Beijing, China.
Tong J; Peking University HuiLongGuan Clinical Medical School, Beijing Huilongguan Hospital, Beijing, China.
Zhou Y; Peking University HuiLongGuan Clinical Medical School, Beijing Huilongguan Hospital, Beijing, China.
Feng W; Peking University HuiLongGuan Clinical Medical School, Beijing Huilongguan Hospital, Beijing, China.
Li Y; Peking University HuiLongGuan Clinical Medical School, Beijing Huilongguan Hospital, Beijing, China.
Chen S; Peking University HuiLongGuan Clinical Medical School, Beijing Huilongguan Hospital, Beijing, China.
Liu Y; Peking University HuiLongGuan Clinical Medical School, Beijing Huilongguan Hospital, Beijing, China.
Wang Z; Peking University HuiLongGuan Clinical Medical School, Beijing Huilongguan Hospital, Beijing, China.
Pan S; Peking University HuiLongGuan Clinical Medical School, Beijing Huilongguan Hospital, Beijing, China.
Zhang P; Peking University HuiLongGuan Clinical Medical School, Beijing Huilongguan Hospital, Beijing, China.
Huang J; Peking University HuiLongGuan Clinical Medical School, Beijing Huilongguan Hospital, Beijing, China.
Yang X; Department of Human Reproductive Medicine, Beijing Obstetrics and Gynecology Hospital, Capital Medical University, Beijing, China; Beijing Maternal and Child Health Care Hospital, Beijing, China.
Li CR; Department of Psychiatry, Yale University School of Medicine, New Haven, CT, USA.
Tian L; Institute of Biomedicine and Translational Medicine, Department of Physiology, Faculty of Medicine, University of Tartu, Tartu, Estonia.
Hong LE; Department of Psychiatry and Behavioral Sciences, University of Texas Health Science Center, Houston, TX 77030, USA.
Tan Y; Peking University HuiLongGuan Clinical Medical School, Beijing Huilongguan Hospital, Beijing, China. Electronic address: .
Pokaż więcej
Źródło :
Progress in neuro-psychopharmacology & biological psychiatry [Prog Neuropsychopharmacol Biol Psychiatry] 2024 Mar 02; Vol. 130, pp. 110926. Date of Electronic Publication: 2023 Dec 24.
Typ publikacji :
Journal Article
MeSH Terms :
Kynurenine*/metabolism
Schizophrenia*/drug therapy
Humans ; Schizophrenia, Treatment-Resistant ; Cytokines ; Inflammation ; Kynurenic Acid
Czasopismo naukowe
Szczegóły
Podgląd okładki
Tytuł :
Navigated and individual α-peak-frequency-guided transcranial magnetic stimulation in male patients with treatment-refractory schizophrenia.
Autorzy :
Tuppurainen H; From the Department of Forensic Psychiatry, University of Eastern Finland, Niuvanniemi Hospital, Kuopio, Finland (Tuppurainen, Hyvärinen, Vaurio, Joensuu, Vanhanen, Aho-Mustonen, Tiihonen); the Department of Clinical Neurophysiology, Kuopio University Hospital, Kuopio, Finland (Määttä, Könönen, Julkunen, Mervaala); the Department of Clinical Radiology, Kuopio University Hospital, Kuopio, Finland (Könönen); the Department of Technical Physics, University of Eastern Finland, Kuopio, Finland (Julkunen); the Primary Health Care Unit, Kuopio University Hospital, Kuopio, Finland (Kautiainen); the Folkhälsan Research Center, Helsinki, Finland (Kautiainen); Institute of Clinical Medicine, University of Eastern Finland, Kuopio, Finland (Mervaala); the Department of Clinical Neuroscience, Karolinska Institutet, and Center for Psychiatry Research, Stockholm City Council, Stockholm, Sweden (Tiihonen) .
Määttä S; From the Department of Forensic Psychiatry, University of Eastern Finland, Niuvanniemi Hospital, Kuopio, Finland (Tuppurainen, Hyvärinen, Vaurio, Joensuu, Vanhanen, Aho-Mustonen, Tiihonen); the Department of Clinical Neurophysiology, Kuopio University Hospital, Kuopio, Finland (Määttä, Könönen, Julkunen, Mervaala); the Department of Clinical Radiology, Kuopio University Hospital, Kuopio, Finland (Könönen); the Department of Technical Physics, University of Eastern Finland, Kuopio, Finland (Julkunen); the Primary Health Care Unit, Kuopio University Hospital, Kuopio, Finland (Kautiainen); the Folkhälsan Research Center, Helsinki, Finland (Kautiainen); Institute of Clinical Medicine, University of Eastern Finland, Kuopio, Finland (Mervaala); the Department of Clinical Neuroscience, Karolinska Institutet, and Center for Psychiatry Research, Stockholm City Council, Stockholm, Sweden (Tiihonen).
Könönen M; From the Department of Forensic Psychiatry, University of Eastern Finland, Niuvanniemi Hospital, Kuopio, Finland (Tuppurainen, Hyvärinen, Vaurio, Joensuu, Vanhanen, Aho-Mustonen, Tiihonen); the Department of Clinical Neurophysiology, Kuopio University Hospital, Kuopio, Finland (Määttä, Könönen, Julkunen, Mervaala); the Department of Clinical Radiology, Kuopio University Hospital, Kuopio, Finland (Könönen); the Department of Technical Physics, University of Eastern Finland, Kuopio, Finland (Julkunen); the Primary Health Care Unit, Kuopio University Hospital, Kuopio, Finland (Kautiainen); the Folkhälsan Research Center, Helsinki, Finland (Kautiainen); Institute of Clinical Medicine, University of Eastern Finland, Kuopio, Finland (Mervaala); the Department of Clinical Neuroscience, Karolinska Institutet, and Center for Psychiatry Research, Stockholm City Council, Stockholm, Sweden (Tiihonen).
Julkunen P; From the Department of Forensic Psychiatry, University of Eastern Finland, Niuvanniemi Hospital, Kuopio, Finland (Tuppurainen, Hyvärinen, Vaurio, Joensuu, Vanhanen, Aho-Mustonen, Tiihonen); the Department of Clinical Neurophysiology, Kuopio University Hospital, Kuopio, Finland (Määttä, Könönen, Julkunen, Mervaala); the Department of Clinical Radiology, Kuopio University Hospital, Kuopio, Finland (Könönen); the Department of Technical Physics, University of Eastern Finland, Kuopio, Finland (Julkunen); the Primary Health Care Unit, Kuopio University Hospital, Kuopio, Finland (Kautiainen); the Folkhälsan Research Center, Helsinki, Finland (Kautiainen); Institute of Clinical Medicine, University of Eastern Finland, Kuopio, Finland (Mervaala); the Department of Clinical Neuroscience, Karolinska Institutet, and Center for Psychiatry Research, Stockholm City Council, Stockholm, Sweden (Tiihonen).
Kautiainen H; From the Department of Forensic Psychiatry, University of Eastern Finland, Niuvanniemi Hospital, Kuopio, Finland (Tuppurainen, Hyvärinen, Vaurio, Joensuu, Vanhanen, Aho-Mustonen, Tiihonen); the Department of Clinical Neurophysiology, Kuopio University Hospital, Kuopio, Finland (Määttä, Könönen, Julkunen, Mervaala); the Department of Clinical Radiology, Kuopio University Hospital, Kuopio, Finland (Könönen); the Department of Technical Physics, University of Eastern Finland, Kuopio, Finland (Julkunen); the Primary Health Care Unit, Kuopio University Hospital, Kuopio, Finland (Kautiainen); the Folkhälsan Research Center, Helsinki, Finland (Kautiainen); Institute of Clinical Medicine, University of Eastern Finland, Kuopio, Finland (Mervaala); the Department of Clinical Neuroscience, Karolinska Institutet, and Center for Psychiatry Research, Stockholm City Council, Stockholm, Sweden (Tiihonen).
Hyvärinen S; From the Department of Forensic Psychiatry, University of Eastern Finland, Niuvanniemi Hospital, Kuopio, Finland (Tuppurainen, Hyvärinen, Vaurio, Joensuu, Vanhanen, Aho-Mustonen, Tiihonen); the Department of Clinical Neurophysiology, Kuopio University Hospital, Kuopio, Finland (Määttä, Könönen, Julkunen, Mervaala); the Department of Clinical Radiology, Kuopio University Hospital, Kuopio, Finland (Könönen); the Department of Technical Physics, University of Eastern Finland, Kuopio, Finland (Julkunen); the Primary Health Care Unit, Kuopio University Hospital, Kuopio, Finland (Kautiainen); the Folkhälsan Research Center, Helsinki, Finland (Kautiainen); Institute of Clinical Medicine, University of Eastern Finland, Kuopio, Finland (Mervaala); the Department of Clinical Neuroscience, Karolinska Institutet, and Center for Psychiatry Research, Stockholm City Council, Stockholm, Sweden (Tiihonen).
Vaurio O; From the Department of Forensic Psychiatry, University of Eastern Finland, Niuvanniemi Hospital, Kuopio, Finland (Tuppurainen, Hyvärinen, Vaurio, Joensuu, Vanhanen, Aho-Mustonen, Tiihonen); the Department of Clinical Neurophysiology, Kuopio University Hospital, Kuopio, Finland (Määttä, Könönen, Julkunen, Mervaala); the Department of Clinical Radiology, Kuopio University Hospital, Kuopio, Finland (Könönen); the Department of Technical Physics, University of Eastern Finland, Kuopio, Finland (Julkunen); the Primary Health Care Unit, Kuopio University Hospital, Kuopio, Finland (Kautiainen); the Folkhälsan Research Center, Helsinki, Finland (Kautiainen); Institute of Clinical Medicine, University of Eastern Finland, Kuopio, Finland (Mervaala); the Department of Clinical Neuroscience, Karolinska Institutet, and Center for Psychiatry Research, Stockholm City Council, Stockholm, Sweden (Tiihonen).
Joensuu M; From the Department of Forensic Psychiatry, University of Eastern Finland, Niuvanniemi Hospital, Kuopio, Finland (Tuppurainen, Hyvärinen, Vaurio, Joensuu, Vanhanen, Aho-Mustonen, Tiihonen); the Department of Clinical Neurophysiology, Kuopio University Hospital, Kuopio, Finland (Määttä, Könönen, Julkunen, Mervaala); the Department of Clinical Radiology, Kuopio University Hospital, Kuopio, Finland (Könönen); the Department of Technical Physics, University of Eastern Finland, Kuopio, Finland (Julkunen); the Primary Health Care Unit, Kuopio University Hospital, Kuopio, Finland (Kautiainen); the Folkhälsan Research Center, Helsinki, Finland (Kautiainen); Institute of Clinical Medicine, University of Eastern Finland, Kuopio, Finland (Mervaala); the Department of Clinical Neuroscience, Karolinska Institutet, and Center for Psychiatry Research, Stockholm City Council, Stockholm, Sweden (Tiihonen).
Vanhanen M; From the Department of Forensic Psychiatry, University of Eastern Finland, Niuvanniemi Hospital, Kuopio, Finland (Tuppurainen, Hyvärinen, Vaurio, Joensuu, Vanhanen, Aho-Mustonen, Tiihonen); the Department of Clinical Neurophysiology, Kuopio University Hospital, Kuopio, Finland (Määttä, Könönen, Julkunen, Mervaala); the Department of Clinical Radiology, Kuopio University Hospital, Kuopio, Finland (Könönen); the Department of Technical Physics, University of Eastern Finland, Kuopio, Finland (Julkunen); the Primary Health Care Unit, Kuopio University Hospital, Kuopio, Finland (Kautiainen); the Folkhälsan Research Center, Helsinki, Finland (Kautiainen); Institute of Clinical Medicine, University of Eastern Finland, Kuopio, Finland (Mervaala); the Department of Clinical Neuroscience, Karolinska Institutet, and Center for Psychiatry Research, Stockholm City Council, Stockholm, Sweden (Tiihonen).
Aho-Mustonen K; From the Department of Forensic Psychiatry, University of Eastern Finland, Niuvanniemi Hospital, Kuopio, Finland (Tuppurainen, Hyvärinen, Vaurio, Joensuu, Vanhanen, Aho-Mustonen, Tiihonen); the Department of Clinical Neurophysiology, Kuopio University Hospital, Kuopio, Finland (Määttä, Könönen, Julkunen, Mervaala); the Department of Clinical Radiology, Kuopio University Hospital, Kuopio, Finland (Könönen); the Department of Technical Physics, University of Eastern Finland, Kuopio, Finland (Julkunen); the Primary Health Care Unit, Kuopio University Hospital, Kuopio, Finland (Kautiainen); the Folkhälsan Research Center, Helsinki, Finland (Kautiainen); Institute of Clinical Medicine, University of Eastern Finland, Kuopio, Finland (Mervaala); the Department of Clinical Neuroscience, Karolinska Institutet, and Center for Psychiatry Research, Stockholm City Council, Stockholm, Sweden (Tiihonen).
Mervaala E; From the Department of Forensic Psychiatry, University of Eastern Finland, Niuvanniemi Hospital, Kuopio, Finland (Tuppurainen, Hyvärinen, Vaurio, Joensuu, Vanhanen, Aho-Mustonen, Tiihonen); the Department of Clinical Neurophysiology, Kuopio University Hospital, Kuopio, Finland (Määttä, Könönen, Julkunen, Mervaala); the Department of Clinical Radiology, Kuopio University Hospital, Kuopio, Finland (Könönen); the Department of Technical Physics, University of Eastern Finland, Kuopio, Finland (Julkunen); the Primary Health Care Unit, Kuopio University Hospital, Kuopio, Finland (Kautiainen); the Folkhälsan Research Center, Helsinki, Finland (Kautiainen); Institute of Clinical Medicine, University of Eastern Finland, Kuopio, Finland (Mervaala); the Department of Clinical Neuroscience, Karolinska Institutet, and Center for Psychiatry Research, Stockholm City Council, Stockholm, Sweden (Tiihonen).
Tiihonen J; From the Department of Forensic Psychiatry, University of Eastern Finland, Niuvanniemi Hospital, Kuopio, Finland (Tuppurainen, Hyvärinen, Vaurio, Joensuu, Vanhanen, Aho-Mustonen, Tiihonen); the Department of Clinical Neurophysiology, Kuopio University Hospital, Kuopio, Finland (Määttä, Könönen, Julkunen, Mervaala); the Department of Clinical Radiology, Kuopio University Hospital, Kuopio, Finland (Könönen); the Department of Technical Physics, University of Eastern Finland, Kuopio, Finland (Julkunen); the Primary Health Care Unit, Kuopio University Hospital, Kuopio, Finland (Kautiainen); the Folkhälsan Research Center, Helsinki, Finland (Kautiainen); Institute of Clinical Medicine, University of Eastern Finland, Kuopio, Finland (Mervaala); the Department of Clinical Neuroscience, Karolinska Institutet, and Center for Psychiatry Research, Stockholm City Council, Stockholm, Sweden (Tiihonen).
Pokaż więcej
Źródło :
Journal of psychiatry & neuroscience : JPN [J Psychiatry Neurosci] 2024 Mar 01; Vol. 49 (2), pp. E87-E95. Date of Electronic Publication: 2024 Mar 01 (Print Publication: 2024).
Typ publikacji :
Journal Article; Randomized Controlled Trial
MeSH Terms :
Schizophrenia*/diagnostic imaging
Schizophrenia*/therapy
Transcranial Magnetic Stimulation*/methods
Humans ; Male ; Double-Blind Method ; Schizophrenia, Treatment-Resistant ; Schizophrenic Psychology
Czasopismo naukowe
Szczegóły
Podgląd okładki
Tytuł :
Efficacy of pharmacological agents for the management of treatment-resistant schizophrenia: a network meta-analysis.
Autorzy :
Mishra A; Department of Pharmacology, All India Institute of Medical Sciences (AIIMS), Bhubaneswar, India.
Maiti R; Department of Pharmacology, All India Institute of Medical Sciences (AIIMS), Bhubaneswar, India.
Mishra BR; Department of Psychiatry, All India Institute of Medical Sciences (AIIMS), Bhubaneswar, India.
Srinivasan A; Department of Pharmacology, All India Institute of Medical Sciences (AIIMS), Bhubaneswar, India.
Pokaż więcej
Źródło :
Expert review of clinical pharmacology [Expert Rev Clin Pharmacol] 2024 Mar; Vol. 17 (3), pp. 293-302. Date of Electronic Publication: 2024 Jan 26.
Typ publikacji :
Meta-Analysis; Journal Article; Review
MeSH Terms :
Schizophrenia*/drug therapy
Antipsychotic Agents*/pharmacology
Antipsychotic Agents*/therapeutic use
Humans ; Schizophrenia, Treatment-Resistant ; Escitalopram ; Network Meta-Analysis ; Bayes Theorem
Czasopismo naukowe
Szczegóły
Podgląd okładki
Tytuł :
CLEAR - clozapine in early psychosis: study protocol for a multi-centre, randomised controlled trial of clozapine vs other antipsychotics for young people with treatment resistant schizophrenia in real world settings.
Autorzy :
Casetta C; Institute of Psychiatry, Psychology & Neuroscience, King's College London, London, UK. .; South London and Maudsley NHS Foundation Trust, London, UK. .
Santosh P; Institute of Psychiatry, Psychology & Neuroscience, King's College London, London, UK.; South London and Maudsley NHS Foundation Trust, London, UK.
Bayley R; Institute of Psychiatry, Psychology & Neuroscience, King's College London, London, UK.
Bisson J; Division of Psychological Medicine and Clinical Neurosciences, Cardiff University, Cardiff, UK.
Byford S; Institute of Psychiatry, Psychology & Neuroscience, King's College London, London, UK.
Dixon C; Wonford House Hospital, Devon Partnership NHS Trust, Exeter, UK.
Drake RJ; Division of Psychology & Mental Health, University of Manchester, Manchester, UK.; Greater Manchester Mental Health NHS Foundation Trust, Manchester, UK.
Elvins R; Manchester University Hospitals NHS Foundation Trust, Manchester, UK.
Emsley R; Institute of Psychiatry, Psychology & Neuroscience, King's College London, London, UK.
Fung N; Birmingham Women's and Children's NHS Foundation Trust, Birmingham, UK.
Hayes D; South London and Maudsley NHS Foundation Trust, London, UK.
Howes O; Institute of Psychiatry, Psychology & Neuroscience, King's College London, London, UK.
James A; Department of Psychiatry, University of Oxford, Oxford, UK.
James K; Institute of Psychiatry, Psychology & Neuroscience, King's College London, London, UK.
Jones R; Birmingham and Solihull Mental Health Foundation Trust, Birmingham, UK.
Killaspy H; Division of Psychiatry, University College London, London, UK.
Lennox B; Department of Psychiatry, University of Oxford, Oxford, UK.
Marchant L; Institute of Psychiatry, Psychology & Neuroscience, King's College London, London, UK.
McGuire P; Department of Psychiatry, University of Oxford, Oxford, UK.
Oloyede E; Institute of Psychiatry, Psychology & Neuroscience, King's College London, London, UK.; South London and Maudsley NHS Foundation Trust, London, UK.
Rogdaki M; Institute of Psychiatry, Psychology & Neuroscience, King's College London, London, UK.; South London and Maudsley NHS Foundation Trust, London, UK.
Upthegrove R; Institute for Mental Health, University of Birmingham, Birmingham, UK.; Birmingham Early Intervention Service, Birmingham Womens and Childrens NHS Foundation Trust, Birmingham, UK.
Walters J; Division of Psychological Medicine and Clinical Neurosciences, Cardiff University, Cardiff, UK.
Egerton A; Institute of Psychiatry, Psychology & Neuroscience, King's College London, London, UK.
MacCabe JH; Institute of Psychiatry, Psychology & Neuroscience, King's College London, London, UK.; South London and Maudsley NHS Foundation Trust, London, UK.
Pokaż więcej
Źródło :
BMC psychiatry [BMC Psychiatry] 2024 Feb 14; Vol. 24 (1), pp. 122. Date of Electronic Publication: 2024 Feb 14.
Typ publikacji :
Clinical Trial Protocol; Journal Article
MeSH Terms :
Antipsychotic Agents*/adverse effects
Clozapine*/adverse effects
Schizophrenia*/therapy
Psychotic Disorders*/drug therapy
Child ; Humans ; Adolescent ; Aged ; Adult ; Young Adult ; Schizophrenia, Treatment-Resistant ; Quality of Life ; Randomized Controlled Trials as Topic ; Multicenter Studies as Topic
Czasopismo naukowe
Szczegóły Pełny tekst Pełny tekst
Podgląd okładki
Tytuł :
A Short Turnaround of Clozapine Blood Level Results Within 6 hours is Essential for Effective Management of Severely Ill Persons with Treatment-Resistant Schizophrenia.
Autorzy :
Vincent PD; Department of Pharmacy, Institut universitaire en santé mentale de Montréal, Montréal, Canada.; Faculty of Pharmacy, Université de Montréal, Montréal, Canada.
Lesage A; Department of Psychiatry, Institut universitaire en santé mentale de Montréal, Montréal, Canada.; Faculty of Medicine, Université de Montréal, Montréal, Canada.
Lalonde P; Department of Psychiatry, Institut universitaire en santé mentale de Montréal, Montréal, Canada.; Faculty of Medicine, Université de Montréal, Montréal, Canada.
Lipp O; Department of Psychiatry, Institut universitaire en santé mentale de Montréal, Montréal, Canada.; Faculty of Medicine, Université de Montréal, Montréal, Canada.
De Guire V; Faculty of Medicine, Université de Montréal, Montréal, Canada.; Department of Biochemistry, Hôpital Maisonneuve-Rosemont, Montréal, Canada.
Desbiens MP; Department of Pharmacy, Institut universitaire en santé mentale de Montréal, Montréal, Canada.
Schoretsanitis G; Department of Psychiatry, Psychotherapy and Psychosomatics, Hospital of Psychiatry, University of Zurich, Zurich, Switzerland.; Department of Psychiatry, The Zucker Hillside Hospital, Northwell Health, Glen Oaks, New York and.; Department of Psychiatry, Zucker School of Medicine at Northwell/Hofstra, Hempstead, New York.
Pokaż więcej
Źródło :
Therapeutic drug monitoring [Ther Drug Monit] 2024 Apr 01; Vol. 46 (2), pp. 274-275. Date of Electronic Publication: 2024 Feb 09.
Typ publikacji :
Journal Article
MeSH Terms :
Clozapine*/therapeutic use
Schizophrenia*/drug therapy
Antipsychotic Agents*/therapeutic use
Humans ; Schizophrenia, Treatment-Resistant
Czasopismo naukowe
Szczegóły
Podgląd okładki
Tytuł :
Insights and improvements: A critical analysis of methodological limitations in the investigation of smoking and valproic acid in treatment-resistant schizophrenia.
Autorzy :
Araujo MB; School of Medicine, Federal University of Ceara, Fortaleza, Ceará, Brazil.
Nogueira GN; School of Medicine, Federal University of Ceara, Fortaleza, Ceará, Brazil.
Silveira PLSD; School of Medicine, Federal University of Ceara, Fortaleza, Ceará, Brazil.
de Souza Júnior SA; University Hospital Walter Cantidio, Federal University of Ceara, Fortaleza, Ceará, Brazil.
de Matos E Souza FG; Psychiatric Service, University Hospital Walter Cantidio, Fortaleza, Ceará, Brazil.; Clinical Medicine Department, Federal University of Ceara, Fortaleza, Ceará, Brazil.
Bisol LW; Psychiatric Service, University Hospital Walter Cantidio, Fortaleza, Ceará, Brazil.; Clinical Medicine Department, Federal University of Ceara, Fortaleza, Ceará, Brazil.
Pokaż więcej
Źródło :
Acta psychiatrica Scandinavica [Acta Psychiatr Scand] 2024 Apr; Vol. 149 (4), pp. 361-362. Date of Electronic Publication: 2024 Jan 23.
Typ publikacji :
Letter
MeSH Terms :
Schizophrenia*/drug therapy
Antipsychotic Agents*/therapeutic use
Humans ; Valproic Acid/therapeutic use ; Schizophrenia, Treatment-Resistant ; Smoking
Opinia redakcyjna
Szczegóły
Podgląd okładki
Tytuł :
Overcoming Obstacles to Clozapine Treatment: A Case of Clozapine Rechallenge in ECT-Resistant Schizophrenia With Catatonic Features.
Autorzy :
Dima A
Abdelsamie A
Clark-Castillo R
Webb-Wilson H
Shergill SS
Stanton B
Gaughran F
Whiskey E
Nettis MA
Pokaż więcej
Źródło :
Journal of clinical psychopharmacology [J Clin Psychopharmacol] 2024 Mar-Apr 01; Vol. 44 (2), pp. 182-185.
Typ publikacji :
Case Reports; Journal Article
MeSH Terms :
Clozapine*/adverse effects
Schizophrenia*/drug therapy
Antipsychotic Agents*/adverse effects
Catatonia*/drug therapy
Electroconvulsive Therapy*
Humans ; Combined Modality Therapy ; Schizophrenia, Catatonic/drug therapy
Czasopismo naukowe
Szczegóły
Podgląd okładki
Tytuł :
Real-World Effectiveness of High-Dose Olanzapine and Clozapine for Treatment-Resistant Schizophrenia in Japan: A Retrospective Bidirectional Mirror-Image Study.
Autorzy :
Watanabe M; From the Yamanashi Prefectural Kita Hospital, Yamanashi.
Misawa F; From the Yamanashi Prefectural Kita Hospital, Yamanashi.
Takeuchi H; Department of Neuropsychiatry, Keio University School of Medicine, Tokyo, Japan.
Pokaż więcej
Źródło :
Journal of clinical psychopharmacology [J Clin Psychopharmacol] 2024 Mar-Apr 01; Vol. 44 (2), pp. 151-156. Date of Electronic Publication: 2024 Jan 27.
Typ publikacji :
Journal Article
MeSH Terms :
Clozapine*
Antipsychotic Agents*
Schizophrenia*/drug therapy
Humans ; Olanzapine/therapeutic use ; Schizophrenia, Treatment-Resistant ; Retrospective Studies ; Japan ; Benzodiazepines/adverse effects
Czasopismo naukowe
Szczegóły
Podgląd okładki
Tytuł :
Virtual twins for model-informed precision dosing of clozapine in patients with treatment-resistant schizophrenia.
Autorzy :
Mostafa S; Centre for Medicine Use and Safety, Monash University, Parkville, Victoria, Australia.; MyDNA Life Australia Limited, Victoria, Australia.
Rafizadeh R; BC Mental Health and Substance Use Services, BC Psychosis Program, Lower Mainland Pharmacy Services, Vancouver, British Columbia, Canada.
Polasek TM; Centre for Medicine Use and Safety, Monash University, Parkville, Victoria, Australia.; Certara, Princeton, New Jersey, USA.; Department of Clinical Pharmacology, Royal Adelaide Hospital, Adelaide, South Australia, Australia.
Bousman CA; Department of Psychiatry, Melbourne Neuropsychiatry Centre, University of Melbourne and Melbourne Health, Melbourne, Victoria, Australia.; Alberta Children's Hospital Research Institute, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada.; Hotchkiss Brain Institute, Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada.; Departments of Medical Genetics, Psychiatry, Physiology and Pharmacology, and Community Health Sciences, University of Calgary, Calgary, Alberta, Canada.
Rostami-Hodjegan A; Centre for Applied Pharmacokinetic Research (CAPKR), School of Health Sciences, University of Manchester, Manchester, UK.; Simcyp Division, Certara UK Limited, Sheffield, UK.
Stowe R; Department of Psychiatry, University of British Columbia, Vancouver, British Columbia, Canada.; Djavid Mowafaghian Centre for Brain Health, University of British Columbia, Vancouver, British Columbia, Canada.; Department of Neurology (Medicine), University of British Columbia, Vancouver, British Columbia, Canada.
Carrion P; Department of Psychiatry, University of British Columbia, Vancouver, British Columbia, Canada.
Sheffield LJ; MyDNA Life Australia Limited, Victoria, Australia.
Kirkpatrick CMJ; Centre for Medicine Use and Safety, Monash University, Parkville, Victoria, Australia.
Pokaż więcej
Źródło :
CPT: pharmacometrics & systems pharmacology [CPT Pharmacometrics Syst Pharmacol] 2024 Mar; Vol. 13 (3), pp. 424-436. Date of Electronic Publication: 2024 Jan 19.
Typ publikacji :
Journal Article
MeSH Terms :
Clozapine*/pharmacokinetics
Clozapine*/therapeutic use
Antipsychotic Agents*/pharmacokinetics
Schizophrenia*/drug therapy
Humans ; Fluvoxamine ; Schizophrenia, Treatment-Resistant
Czasopismo naukowe
Szczegóły Pełny tekst Pełny tekst
Podgląd okładki
Tytuł :
Evenamide: A Potential Pharmacotherapeutic Alternative for Treatment-Resistant Schizophrenia.
Autorzy :
Singh R; Schizophrenia Division, the Centre for Addiction and Mental Health, Toronto, ON, Canada.
Hahn MK; Schizophrenia Division, the Centre for Addiction and Mental Health, Toronto, ON, Canada.; Institute of Medical Sciences, University of Toronto, Toronto, ON, Canada.; Department of Psychiatry, University of Toronto, Toronto, ON, Canada.; Banting and Best Diabetes Centre, University of Toronto, Toronto, ON, Canada.
Bansal Y; Neurobiology of Depression and Aging Lab, the Centre for Addiction and Mental Health, Toronto, ON, Canada.
Agarwal SM; Schizophrenia Division, the Centre for Addiction and Mental Health, Toronto, ON, Canada.; Institute of Medical Sciences, University of Toronto, Toronto, ON, Canada.; Department of Psychiatry, University of Toronto, Toronto, ON, Canada.; Banting and Best Diabetes Centre, University of Toronto, Toronto, ON, Canada.
Remington G; Schizophrenia Division, the Centre for Addiction and Mental Health, Toronto, ON, Canada.; Institute of Medical Sciences, University of Toronto, Toronto, ON, Canada.; Department of Psychiatry, University of Toronto, Toronto, ON, Canada.
Pokaż więcej
Źródło :
The international journal of neuropsychopharmacology [Int J Neuropsychopharmacol] 2024 Feb 01; Vol. 27 (2).
Typ publikacji :
Journal Article
MeSH Terms :
Schizophrenia*/drug therapy
Antipsychotic Agents*/therapeutic use
Humans ; Schizophrenia, Treatment-Resistant
Czasopismo naukowe
Szczegóły
Podgląd okładki
Tytuł :
The kynurenine pathway in treatment-resistant schizophrenia at the crossroads between pathophysiology and pharmacotherapy.
Autorzy :
Sapienza J; Department of Clinical Neurosciences, IRCCS San Raffaele Scientific Institute, Milan, Italy; Department of Humanities and Life Sciences, University School for Advanced Studies IUSS, Pavia, Italy.
Agostoni G; Department of Clinical Neurosciences, IRCCS San Raffaele Scientific Institute, Milan, Italy.
Dall'Acqua S; Department of Pharmaceutical and Pharmacological Sciences, University of Padua, Padua, Italy.
Sut S; Department of Pharmaceutical and Pharmacological Sciences, University of Padua, Padua, Italy.
Nasini S; Department of Pharmaceutical and Pharmacological Sciences, University of Padua, Padua, Italy.
Martini F; Department of Clinical Neurosciences, IRCCS San Raffaele Scientific Institute, Milan, Italy.
Marchesi A; Department of Clinical Neurosciences, IRCCS San Raffaele Scientific Institute, Milan, Italy.
Bechi M; Department of Clinical Neurosciences, IRCCS San Raffaele Scientific Institute, Milan, Italy.
Buonocore M; Department of Clinical Neurosciences, IRCCS San Raffaele Scientific Institute, Milan, Italy.
Cocchi F; Department of Clinical Neurosciences, IRCCS San Raffaele Scientific Institute, Milan, Italy.
Cavallaro R; Department of Clinical Neurosciences, IRCCS San Raffaele Scientific Institute, Milan, Italy; School of Medicine, Vita-Salute San Raffaele University, Milan, Italy.
Spangaro M; Department of Clinical Neurosciences, IRCCS San Raffaele Scientific Institute, Milan, Italy. Electronic address: .
Comai S; Department of Pharmaceutical and Pharmacological Sciences, University of Padua, Padua, Italy; Division of Neurosciences, IRCCS San Raffaele Scientific Institute, Milan, Italy; Department of Psychiatry, McGill University, Montreal, QC, Canada; Department of Biomedical Sciences, University of Padua, Padua, Italy. Electronic address: .
Bosia M; Department of Clinical Neurosciences, IRCCS San Raffaele Scientific Institute, Milan, Italy; School of Medicine, Vita-Salute San Raffaele University, Milan, Italy.
Pokaż więcej
Źródło :
Schizophrenia research [Schizophr Res] 2024 Feb; Vol. 264, pp. 71-80. Date of Electronic Publication: 2023 Dec 14.
Typ publikacji :
Journal Article
MeSH Terms :
Schizophrenia*/drug therapy
Clozapine*/therapeutic use
Humans ; Kynurenine/metabolism ; Schizophrenia, Treatment-Resistant ; Cross-Sectional Studies ; Biomarkers ; Kynurenic Acid ; Quinolinic Acid
Czasopismo naukowe
Szczegóły
Podgląd okładki
Tytuł :
Potential impact on mental health in patients with treatment-resistant schizophrenia - clozapine augmentation with long-acting parenteral antipsychotics: a case series.
Autorzy :
Nováková M
Hammer T
Nováková E
Mayerová M
Ustohal L
Kotolová H
Pokaż więcej
Transliterated Title :
Možnost ovlivnění duševního zdraví u pacientů s farmakorezistentní schizofrení – augmentace klozapinu dlouhodobě působícími parenterálními antipsychotiky: série případů.
Źródło :
Ceska a Slovenska farmacie : casopis Ceske farmaceuticke spolecnosti a Slovenske farmaceuticke spolecnosti [Ceska Slov Farm] 2024; Vol. 72 (6), pp. 277-287.
Typ publikacji :
Journal Article
MeSH Terms :
Antipsychotic Agents*/adverse effects
Clozapine*/adverse effects
Schizophrenia*/drug therapy
Schizophrenia*/chemically induced
Humans ; Schizophrenia, Treatment-Resistant ; Mental Health ; Retrospective Studies
Czasopismo naukowe
Szczegóły
Podgląd okładki
Tytuł :
Treatment of schizophrenia with catatonic symptoms: A narrative review.
Autorzy :
Caroff SN; Behavioral Health Service, Corporal Michael J. Crescenz VA Medical Center and the Department of Psychiatry, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA. Electronic address: .
Ungvari GS; Division of Psychiatry, School of Medicine, University of Western Australia, Crawley, Australia; Section of Psychiatry, University of Notre Dame, Fremantle, Australia.
Gazdag G; Department of Psychiatry and Psychiatric Rehabilitation, Jahn Ferenc South Pest Hospital, Budapest, Hungary; Department of Psychiatry and Psychotherapy, Faculty of Medicine, Semmelweis University, Budapest, Hungary.
Pokaż więcej
Źródło :
Schizophrenia research [Schizophr Res] 2024 Jan; Vol. 263, pp. 265-274. Date of Electronic Publication: 2022 Nov 18.
Typ publikacji :
Review; Journal Article
MeSH Terms :
Schizophrenia*/complications
Schizophrenia*/drug therapy
Catatonia*/diagnosis
Catatonia*/etiology
Catatonia*/therapy
Psychotic Disorders*/psychology
Antipsychotic Agents*/therapeutic use
Neuroleptic Malignant Syndrome*
Humans ; Schizophrenia, Catatonic/complications ; Schizophrenia, Catatonic/diagnosis ; Schizophrenia, Catatonic/drug therapy
Czasopismo naukowe
Szczegóły
Podgląd okładki
Tytuł :
Response to the letter to the Editor from Araujo and colleagues on the research article entitled, "Effect of smoking habits and concomitant valproic acid use on relapse in patients with treatment-resistant schizophrenia receiving clozapine: A 1-year retrospective cohort study".
Autorzy :
Tsukahara M; Department of Psychiatry, Okayama Psychiatric Medical Center, Okayama, Japan.
So R; Department of Psychiatry, Okayama Psychiatric Medical Center, Okayama, Japan.
Yoshimura Y; Department of Psychiatry, Ajino Clinic, Okayama, Japan.
Nakajima S; Department of Neuropsychiatry, Keio University School of Medicine, Tokyo, Japan.
Takeuchi H; Department of Neuropsychiatry, Keio University School of Medicine, Tokyo, Japan.
Pokaż więcej
Źródło :
Acta psychiatrica Scandinavica [Acta Psychiatr Scand] 2024 May; Vol. 149 (5), pp. 436-438. Date of Electronic Publication: 2024 Feb 15.
Typ publikacji :
Letter
MeSH Terms :
Clozapine*/therapeutic use
Schizophrenia*/drug therapy
Schizophrenia*/chemically induced
Antipsychotic Agents*/therapeutic use
Humans ; Valproic Acid/pharmacology ; Valproic Acid/therapeutic use ; Smoking ; Schizophrenia, Treatment-Resistant ; Retrospective Studies ; Chronic Disease ; Recurrence ; Habits
Opinia redakcyjna
Szczegóły
Podgląd okładki
Tytuł :
The longitudinal structure of negative symptoms in treatment resistant schizophrenia.
Autorzy :
Wolpe N; Department of Physical Therapy, The Stanley Steyer School of Health Professions, Faculty of Medicine, Tel Aviv University, Tel Aviv 6997801, Israel; Sagol School of Neuroscience, Tel Aviv University, Tel Aviv 6997801, Israel; Department of Psychiatry, University of Cambridge, Cambridge CB2 0SZ, UK.
Vituri A; Tel Aviv Center for Artificial Intelligence & Data Science (TAD), Tel Aviv University, 6997801, Israel.
Jones PB; Department of Psychiatry, University of Cambridge, Cambridge CB2 0SZ, UK; Cambridgeshire and Peterborough NHS Foundation Trust, Fulbourn, Cambridge CB21 5EF, UK.
Shahar M; Tel Aviv Center for Artificial Intelligence & Data Science (TAD), Tel Aviv University, 6997801, Israel.
Fernandez-Egea E; Department of Psychiatry, University of Cambridge, Cambridge CB2 0SZ, UK; Cambridgeshire and Peterborough NHS Foundation Trust, Fulbourn, Cambridge CB21 5EF, UK. Electronic address: .
Pokaż więcej
Źródło :
Comprehensive psychiatry [Compr Psychiatry] 2024 Jan; Vol. 128, pp. 152440. Date of Electronic Publication: 2023 Nov 27.
Typ publikacji :
Journal Article
MeSH Terms :
Schizophrenia*/diagnosis
Schizophrenia*/drug therapy
Schizophrenia*/complications
Clozapine*/adverse effects
Psychotic Disorders*/complications
Humans ; Schizophrenia, Treatment-Resistant ; Psychiatric Status Rating Scales
Czasopismo naukowe
Szczegóły
Podgląd okładki
Tytuł :
Side effects of clozapine in older adults with treatment-resistant schizophrenia compared to younger adults.
Autorzy :
Groenewald FCE; University of Utrecht, Utrecht, The Netherlands.
Kok RM; Department Old Age Psychiatry, Parnassia Group, Den Haag, The Netherlands.
Pokaż więcej
Źródło :
International journal of geriatric psychiatry [Int J Geriatr Psychiatry] 2024 Jan; Vol. 39 (1), pp. e6051.
Typ publikacji :
Journal Article
MeSH Terms :
Clozapine*/adverse effects
Schizophrenia*/drug therapy
Humans ; Aged ; Schizophrenia, Treatment-Resistant ; Retrospective Studies ; Mental Health
Czasopismo naukowe
Szczegóły
Wyświetlanie 1-20 z 717440

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies